Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study

BACKGROUND: Patients with type 2 diabetes (T2D) and coronary artery disease (CAD) have increased risk of cardiac dysfunction. The diabetic heart is characterized by increased fatty acid oxidation and reduced glucose uptake resulting in reduced cardiac efficiency. Glucagon-like peptide-1 (GLP-1) has...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cardiovasc Diabetol
Hlavní autoři: Kumarathurai, Preman, Anholm, Christian, Nielsen, Olav W., Kristiansen, Ole P., Mølvig, Jens, Madsbad, Sten, Haugaard, Steen B., Sajadieh, Ahmad
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2016
Témata:
Original Investigation
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4960858/
https://ncbi.nlm.nih.gov/pubmed/27455835
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-016-0425-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky